Compare PPSI & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPSI | XGN |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Electrical Products | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 64.5M |
| IPO Year | 2008 | 2014 |
| Metric | PPSI | XGN |
|---|---|---|
| Price | $3.18 | $2.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $12.00 | $9.14 |
| AVG Volume (30 Days) | 69.4K | ★ 288.5K |
| Earning Date | 05-14-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1626.32 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,879,000.00 | N/A |
| Revenue This Year | $26.84 | $8.06 |
| Revenue Next Year | $10.26 | $12.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.26 | $2.65 |
| 52 Week High | $5.70 | $12.23 |
| Indicator | PPSI | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 30.03 |
| Support Level | $2.96 | N/A |
| Resistance Level | $4.05 | $3.89 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 21.05 | 3.46 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.